Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

An article from

News roundup

Inhibrx, the subject of recent buyout rumors, showed its drug might enhance the effects of Keytruda. Elsewhere, Capricor sued its cell therapy partner and Argenx got a revenue boost.

Published May 11, 2026

Getty Images

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

Other newsrooms on this story

Related reading

FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended

Avalo shares spike on skin drug data; BioNTech to cut staff

Astellas treatment offers new hope to a devastated rare disease community

Are analysts too quick to gloss over Lilly's liver case?

Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B

BeOne wins FDA approval in lymphoma race